Literature DB >> 18180793

Antibody diversification by somatic mutation: from Burnet onwards.

Michael S Neuberger1.   

Abstract

The clonal selection theory proposed by Burnet required a genetic process, for which there was then no precedent, which randomizes the region of the gene(s) responsible for the specification of gamma-globulin molecules. Work over the subsequent half-century substantiated Burnet's speculation, revealing two distinct novel genetic processes. During early development (when Burnet first thought the randomization took place) programmed gene segment rearrangement catalysed by the RAG1/RAG2 recombinase generates a substantial diversity of immunoglobulin molecules (the primary repertoire). Somatic hypermutation (triggered by the activation-induced deaminase (AID) DNA deaminase) then occurs following antigen encounter in man and mouse, yielding a secondary repertoire. This hypermutation allows both limitless diversification as well as maturation of the antibody response by a process of somatic evolution akin to that envisioned by Burnet in later formulations of the clonal selection theory. AID-triggered antigen receptor diversification probably arose earlier in evolution than RAG-mediated repertoire generation. Here I trace our insights into the molecular mechanism antibody somatic mutation from when it was first proposed through to our current understanding of how it is triggered by targeted deamination of deoxycytidine residues in immunoglobulin gene DNA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180793     DOI: 10.1038/sj.icb.7100160

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  33 in total

1.  Evolution and immunity.

Authors:  Jim Kaufman
Journal:  Immunology       Date:  2010-05-11       Impact factor: 7.397

Review 2.  Structure and function of immunoglobulins.

Authors:  Harry W Schroeder; Lisa Cavacini
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

Review 3.  What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection?

Authors:  Christopher T Stamper; Patrick C Wilson
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 4.  Activation-induced cytidine deaminase and aberrant germinal center selection in the development of humoral autoimmunities.

Authors:  Ahmad Zaheen; Alberto Martin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 5.  A guide to the perplexed on the specificity of antibodies.

Authors:  Clifford B Saper
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

6.  The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes.

Authors:  Honyin Chiu; Leandra V Jackson; Kwon Ik Oh; Annie Mai; Ze'ev A Ronai; Davide Ruggero; David A Fruman
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

Review 7.  Proper application of antibodies for immunohistochemical detection: antibody crimes and how to prevent them.

Authors:  Richard Ivell; Katja Teerds; Gloria E Hoffman
Journal:  Endocrinology       Date:  2014-01-15       Impact factor: 4.736

Review 8.  The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Authors:  Stephen L Hauser
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

9.  The interaction between AID and CIB1 is nonessential for antibody gene diversification by gene conversion or class switch recombination.

Authors:  Zachary L Demorest; Donna A MacDuff; William L Brown; Scott G Morham; Leslie V Parise; Reuben S Harris
Journal:  PLoS One       Date:  2010-07-20       Impact factor: 3.240

Review 10.  The origin of recurrent translocations in recombining lymphocytes: a balance between break frequency and nuclear proximity.

Authors:  Pedro P Rocha; Jane A Skok
Journal:  Curr Opin Cell Biol       Date:  2013-03-13       Impact factor: 8.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.